Edge Wealth Management’s ProQR Therapeutics PRQR Stock Holding History

Edge Wealth Management’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-199	Closed	-$2K	–	364
2021 Q4	$2K	Hold	199	–	–	﹤0.01%	434
2021 Q3	$2K	Hold	199	–	–	﹤0.01%	449
2021 Q2	$1K	Hold	199	–	–	﹤0.01%	412
2021 Q1	$1K	Hold	199	–	–	﹤0.01%	410
2020 Q4	$1K	Hold	199	–	–	﹤0.01%	356
2020 Q3	$1K	Buy	+199	New	+$1.04K	﹤0.01%	410

Other funds holding PRQR

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Edge Wealth Management's PRQR Position: Q1 2022 in Review

Edge Wealth Management sold out of ProQR Therapeutics (PRQR) in Q1 2022, closing a stake of 199 shares — an estimated $2K sold.

Edge Wealth Management first reported a position in PRQR in Q3 2020 and held it in 6 quarters. The position peaked at $2K in Q4 2021. 58 funds tracked by Wall St. Rank hold PRQR as of Q1 2022.

Edge Wealth Management reported no remaining ProQR Therapeutics position as of Q1 2022 after selling out during the quarter.
Edge Wealth Management sold 199 ProQR Therapeutics shares in Q1 2022, an estimated $2K.
Edge Wealth Management first reported a position in ProQR Therapeutics in Q3 2020 and held it in 6 quarters.
Edge Wealth Management's ProQR Therapeutics position peaked at $2K in Q4 2021.
58 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2022.

Based on Edge Wealth Management's 13F filing for Q1 2022, filed 14 Apr 2022.